

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION
INVESTMENT IN AND CONSTRUCTION OF THE HEALTH CONSUMER
PRODUCTS INDUSTRIAL PARK

This announcement is made by China Resources Pharmaceutical Group Limited (the “**Company**” together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company hereby announces that Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司), (“**Dong-E-E-Jiao**”), a non-wholly-owned subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000423), has resolved to invest in and construct a health consumer products industrial park (the “**Health Consumer Products Industrial Park**”) (the “**Proposed Project**”).

The Health Consumer Products Industrial Park is expected to include manufacturing facilities and supporting warehousing and logistics facilities for health consumer products (such as medicine and homologous food, health care products and functional foods), quality inspection centers, new product incubation centers, and e-commerce sorting and finished drugs warehouses, among others. It is currently contemplated the main features of the Proposed Project are as follows:

Location

The Health Consumer Products Industrial Park is expected to be located at Dong-E County Economic Development Zone, Liaocheng City, Shandong Province, China.

Scope of construction

The total land area of the Health Consumer Products Industrial Park is expected to be approximately 406,800 square meters, and the proposed construction area is expected to be 151,100 square meters, including manufacturing facilities for E-Jiao cake, E-Jiao dates and E-Jiao powder, among others, supporting comprehensive warehouses, e-commerce centers and other storage facilities, quality inspection and incubation centers to meet inspection and new product demands, and public facilities such as sewage treatment and power supply facilities.

Construction period	The construction period is expected to be approximately 22 months from the start of on-site construction to the completion and acceptance of the project.
Investment amount	It is expected that the total investment amount will be approximately RMB1.485 billion, representing a fixed asset investment amount of approximately RMB1.421 billion and initial working capital of approximately RMB64 million.
Source of funding	The Proposed Project is expected to be funded by internal resources of Dong-E-E-Jiao.

The investment in and construction of the Health Consumer Products Industrial Park is a necessary implementation of Dong-E-E-Jiao's "1238" strategy, which involves creating a "Dong-E-E-Jiao model" for the high-quality development of traditional Chinese medicine, building a robust "two-wheel driven" business growth model of pharmaceuticals + health consumer products, expanding the health consumer products business on top of the pharmaceuticals business, cultivating a second growth curve, and facilitating cross-segment promotion and empowerment of the two major businesses. The Proposed Project is also in line with the urgent need for the development of Dong-E-E-Jiao's health consumer products business. Dong-E-E-Jiao's existing industrial park has been facing issues such as limited areas for production expansion and constricted main production line capacity, which cannot meet its development needs of swiftly upgrading health consumer products. In addition, self-built facilities would be beneficial in building Dong-E-E-Jiao's core advantages in the field of health consumer products. Dong-E-E-Jiao's health consumer products are mainly E-Jiao series products, and by establishing production at the Dong-E County origin, it is expected that Dong-E-E-Jiao's regional brand will be strengthened, further strengthening its core competitiveness, systematically building brand positions, and controlling long-term costs.

The investment in and construction of the Health Consumer Products Industrial Park is subject to acquisition of the land parcel for the Proposed Project and the execution of the construction agreement and the terms and conditions as set forth therein. The Company will comply with the applicable requirements under Chapter 14 of the Listing Rules upon the execution of the relevant transaction agreements as and if required.

As of the date of this announcement, the land parcel for the Health Consumer Products Industrial Park has not yet been acquired and no definitive construction agreement has been entered into by the Group for the Proposed Project. The Proposed Project is subject to various factors, including execution of relevant agreements and conditions as set forth therein. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 10 February 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.